A Comparison Between Clobetasol Propionate 0.05% (Clobex®) Spray and Clobetasol Propionate 0.05% (Olux®) Foam

A Comparison Between Clobetasol Propionate (Clobex®) Spray and Clobetasol Propionate (Olux®) Foam With Regard to Efficacy, Safety, Preference and Duration of Response in Stable Plaque Psoriasis

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00436540

Enrollment

Registered

2007-02-19

Start date

2006-03-31

Completion date

2007-01-31

Last updated

2022-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis

Brief summary

The primary objective of this study is to evaluate the efficacy and safety of clobetasol propionate 0.05% (Clobex®) spray compared to clobetasol propionate 0.05% (Olux®) foam.

Detailed description

Same as above.

Interventions

DRUGClobetasol Propionate 0.05% Spray

Apply to affected areas twice daily

DRUGClobetasol Propionate 0.05% Foam

Apply to affected areas twice daily

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Subjects must have a clinical diagnosis of moderate to severe plaque psoriasis, defined as 3%-20% of the body surface area involved

Exclusion criteria

* Subjects who have surface area involvement too large that would require more than 50 grams per week of Clobex® spray or more than 50 grams per week of Olux® foam * Subjects whose psoriasis involves the scalp, face or groin * Subjects with non-plaque psoriasis or other related diseases not classified as plaque psoriasis

Design outcomes

Primary

Measure	Time frame
Efficacy - Body Surface Area, Investigator Global Severity	6 weeks

Secondary

Measure	Time frame
Safety - Tolerability assessments, adverse events	6 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026